Edward Tenthoff
Stock Analyst at Piper Sandler
(3.58)
# 968
Out of 5,182 analysts
198
Total ratings
44.79%
Success rate
7.16%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $8 → $16 | $8.62 | +85.61% | 3 | Apr 27, 2026 | |
| GENB Generate Biomedicines | Initiates: Overweight | $24 | $12.43 | +93.08% | 1 | Mar 24, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 → $110 | $51.75 | +112.56% | 8 | Mar 17, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $45 → $58 | $33.70 | +72.11% | 3 | Mar 13, 2026 | |
| IBRX ImmunityBio | Reiterates: Overweight | $7 → $12 | $7.01 | +71.18% | 1 | Mar 4, 2026 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.70 | +253.98% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $10.23 | +95.50% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $47.33 | +45.78% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.21 | +81.41% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $18.80 | +96.86% | 4 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 → $110 | $69.60 | +58.05% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $1.88 | +325.53% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $98 → $125 | $84.36 | +48.17% | 5 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 → $23 | $7.48 | +207.49% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.16 | +417.24% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $302.38 | +61.72% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.37 | +174.60% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $9.57 | +56.74% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $35.32 | -43.37% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.60 | +337.50% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.04 | +166.08% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.21 | +57.79% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $23.79 | +227.87% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.11 | +147.73% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $1.68 | +3,764.45% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.94 | +2,033.22% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.22 | +146.91% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $90 | $13.03 | +590.71% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.30 | +361.54% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.87 | +168.10% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $4.09 | +2,100.49% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $7.16 | +2,413.97% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.70 | +148.58% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $4.67 | +692.29% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $4.89 | +239,710,323.53% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $771.37 | -54.11% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $428.30 | -24.59% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.25 | +143.90% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $45.10 | -20.18% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.41 | +1,673.05% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.62 | +24,093.55% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $734.40 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $18.30 | +5,714.21% | 2 | Apr 15, 2013 |
Karyopharm Therapeutics
Apr 27, 2026
Reiterates: Overweight
Price Target: $8 → $16
Current: $8.62
Upside: +85.61%
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $24
Current: $12.43
Upside: +93.08%
CRISPR Therapeutics AG
Mar 17, 2026
Reiterates: Overweight
Price Target: $105 → $110
Current: $51.75
Upside: +112.56%
Capricor Therapeutics
Mar 13, 2026
Reiterates: Overweight
Price Target: $45 → $58
Current: $33.70
Upside: +72.11%
ImmunityBio
Mar 4, 2026
Reiterates: Overweight
Price Target: $7 → $12
Current: $7.01
Upside: +71.18%
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.70
Upside: +253.98%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $10.23
Upside: +95.50%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $47.33
Upside: +45.78%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.21
Upside: +81.41%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $18.80
Upside: +96.86%
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $69.60
Upside: +58.05%
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.88
Upside: +325.53%
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $84.36
Upside: +48.17%
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $7.48
Upside: +207.49%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.16
Upside: +417.24%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $302.38
Upside: +61.72%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.37
Upside: +174.60%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $9.57
Upside: +56.74%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $35.32
Upside: -43.37%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.60
Upside: +337.50%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.04
Upside: +166.08%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.21
Upside: +57.79%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $23.79
Upside: +227.87%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.11
Upside: +147.73%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $1.68
Upside: +3,764.45%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.94
Upside: +2,033.22%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.22
Upside: +146.91%
Jul 26, 2024
Maintains: Overweight
Price Target: $240 → $90
Current: $13.03
Upside: +590.71%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.30
Upside: +361.54%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.87
Upside: +168.10%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $4.09
Upside: +2,100.49%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $7.16
Upside: +2,413.97%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.70
Upside: +148.58%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $4.67
Upside: +692.29%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $4.89
Upside: +239,710,323.53%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $771.37
Upside: -54.11%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $428.30
Upside: -24.59%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.25
Upside: +143.90%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $45.10
Upside: -20.18%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.41
Upside: +1,673.05%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.62
Upside: +24,093.55%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $734.40
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $18.30
Upside: +5,714.21%